Neurocrine Biosciences Inc. Revenue 2009–2025
Neurocrine Biosciences Inc. annual/quarterly revenue history and growth rate from 2009 to 2026. Revenue can be defined as the amount of money a company receives from its customers in exchange for the sale of goods or services. Revenue is the top line item on an income statement from which all costs and expenses are subtracted to arrive at net income.
- Neurocrine Biosciences Inc. revenue for the quarter ending March 31, 2026 was 814.5 M, a 42.25% increase year-over-year.
- Neurocrine Biosciences Inc. revenue for the twelve months ending March 31, 2026 was 2.9 B, a 28.89% increase year-over-year.
- Neurocrine Biosciences Inc. annual revenue for 2025 was 2.9 B, a 21.45% increase from 2024.
- Neurocrine Biosciences Inc. annual revenue for 2024 was 2.4 B, a 24.81% increase from 2023.
- Neurocrine Biosciences Inc. annual revenue for 2023 was 1.9 B, a 26.76% increase from 2022.
- Neurocrine Biosciences Inc. annual revenue for 2022 was 1.5 B.
Neurocrine Biosciences Inc. (NBIX) — Frequently Asked Questions
Neurocrine Biosciences Inc. (NBIX) is a publicly traded US company. It has a market capitalization of $16.68B. In fiscal 2025 it reported revenue of $2.86B and net income of $479M. Explore NBIX's stock price, financial statements, earnings history, margins and key ratios below.
What is Neurocrine Biosciences Inc.'s market cap?
Neurocrine Biosciences Inc. (NBIX) has a market capitalization of $16.68B.
What is the NBIX stock price?
NBIX trades at $162.71 (+1.15% on the day).
How much revenue does Neurocrine Biosciences Inc. make?
Neurocrine Biosciences Inc. reported revenue of $2.86B in fiscal 2025.
Is NBIX profitable?
In fiscal 2025, Neurocrine Biosciences Inc. reported net income of $479M.